Therefore, targeting HSP90 is a promising and effective strategy for addressing cancer resistance,115, 158, 159, 160 and various HSP90 inhibitors have been developed and are currently undergoing evaluation in preclinical and clinical settings.23, 29, 161, 162, 163, 164. This evidence concerns the gene HSP90AB1 and cancer.